Trial Profile
An Open-Label, Multi-Center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Luminespib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 19 Jul 2012 Actual number of patients changed from 70 to 29, as reported by ClinicalTrials.gov.
- 19 Jul 2012 Actual end date changed from Feb 2011 to Jan 2011, as reported by ClinicalTrials.gov.
- 10 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.